Patients’ profiles in whom it is worth to use metformin Review article
Article Sidebar
Published:
Dec 31, 2019
Keywords:
metformin, type 2 diabetes mellitus, renal failure, polycystic ovary syndrome, prediabetes, impaired fasting glucose, impaired glucose tolerance
Main Article Content
Abstract
Metformin is main drug in type 2 diabetes mellitus therapy. It is recommended to use it at every stage of treatment, also during insulin therapy. This drug should be used in prediabetes, type 2 diabetes mellitus as monotherapy and in conjunction with other oral drugs and with the insulin. Moreover, there are benefits from using metformin in polycystic ovary syndrome. Main contraindication to use metformin is renal failure. While eGFR is within the range of 44–30 ml/ min/1,73 m2 it is necessary to reduce 50% of dose. If eGFR decrease under 30 ml/min/1,73 m2, using of metformin is forbidden.
Article Details
How to Cite
Gajda , P., Pasterczyk-Bielska, K., & Dzida , G. (2019). Patients’ profiles in whom it is worth to use metformin. Medycyna Faktow (J EBM), 12(4(45), 340-343. https://doi.org/10.24292/01.MF.0419.5
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Dujic T., Zhou K., Donnelly L.A. et al.: Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes 2015; 64(5): 1786-1793. doi: 10.2337/db14-1388.
2. 2019 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clin. Diabet. 2019; 8: 1.
3. Bailey C.J., Turner R.C.: Metformin. N. Engl. J. Med. 1996; 334: 574-579.
4. Barzilai N., Crandall J.P., Kritchevsky S.B., Espeland M.A.: Metformin as a Tool to Target Aging. Cell. Metab. 2016; 23(6): 1060-1065.
5. Brown J.B., Conner C., Nichols G.A.: Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 2010; 33: 501-506.
6. Charakterystyka produktu leczniczego – preparaty metforminy.
7. Diabetes Prevention Program Research Group: Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015; 3: 866-875.
8. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
9. Landman G.W., Kleefstra N., van Hateren K.J. et al.: Metformin associated with lower cander mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33: 322-326.
10. Lipska K.J., Bailey C.J., Inzucchi S.E.: Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011; 34: 1431-1437.
2. 2019 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clin. Diabet. 2019; 8: 1.
3. Bailey C.J., Turner R.C.: Metformin. N. Engl. J. Med. 1996; 334: 574-579.
4. Barzilai N., Crandall J.P., Kritchevsky S.B., Espeland M.A.: Metformin as a Tool to Target Aging. Cell. Metab. 2016; 23(6): 1060-1065.
5. Brown J.B., Conner C., Nichols G.A.: Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 2010; 33: 501-506.
6. Charakterystyka produktu leczniczego – preparaty metforminy.
7. Diabetes Prevention Program Research Group: Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015; 3: 866-875.
8. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
9. Landman G.W., Kleefstra N., van Hateren K.J. et al.: Metformin associated with lower cander mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33: 322-326.
10. Lipska K.J., Bailey C.J., Inzucchi S.E.: Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011; 34: 1431-1437.